Glucagon receptor antagonism induces increased cholesterol absorption

Journal of Lipid Research

Volumn 56, Issue 11, 2015, Pages 2183-2195

  Guan, Hong Ping ^a   Yang, Xiaodong ^a   Lu, Ku ^a   Wang, Sheng Ping ^a   Castro Perez, Jose M ^a   Previs, Stephen ^a   Wright, Michael ^a   Shah, Vinit ^a   Herath, Kithsiri ^a   Xie, Dan ^a   Szeto, Daphne ^a   Forrest, Gail ^a   Xiao, Jing Chen ^a   Palyha, Oksana ^a   Sun, Li Ping ^a   Andryuk, Paula J ^b   Engel, Samuel S ^b   Xiong, Yusheng ^a   Lin, Songnian ^a   Kelley, David E ^a   Erion, Mark D ^a   Davis, Harry R ^c   Wang, Liangsu ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Research   (United States)

^c CVPATH INSTITUTE   (United States)

Author keywords

Bile acids; Cholesterol absorption; Diabetes; Glucagon receptor antagonist; Glucagon like peptide 2; Hypercholesterolemia

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 2; GLUCAGON RECEPTOR; GRA 1; GRA 2; MK 0893; SERINE PROTEINASE; UNCLASSIFIED DRUG; BETA ALANINE; CHOLESTEROL; N-((4-(1-(3-(3,5-DICHLOROPHENYL)-5-(6-METHOXYNAPHTHALEN-2-YL)-1H-PYRAZOL-1-YL)ETHYL)PHENYL)CARBONYL)-BETA-ALANINE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIDIABETIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FLUOROIMMUNOASSAY; GAS CHROMATOGRAPHY; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID ABSORPTION; LIPID ANALYSIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; HYPERCHOLESTEROLEMIA; IC50; INTESTINE ABSORPTION; PRECLINICAL STUDY; TRANSGENIC MOUSE;

ANIMALS; BETA-ALANINE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERCHOLESTEROLEMIA; INHIBITORY CONCENTRATION 50; INTESTINAL ABSORPTION; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRAZOLES; RECEPTORS, GLUCAGON;

EID: 84948761469     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M060897     Document Type: Article

References (59)

1. Müller, W. A., G. R. Faloona, E. Aguilar-Parada, and R. H. Unger . 1970 . Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283 : 109 - 115 .
2. Unger, R. H., and A. D. Cherrington . 2012 . Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122 : 4 - 12 .
3. Engel, S. S., L. Xu, P. J. Andryuk, M. J. Davies, J. Amatruda, K. Kaufman, and B. J. Goldstein . 2011 . Effi cacy and tolerability of MK- 0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM). Diabetes . 60 ( Suppl 1 ): A85.
4. Engel, S. S., M. Reitman, L. Xu, P. J. Andryuk, M. J. Davies, K. Kaufman, and B. J. Goldstein . 2012 . Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes. Diabetes . 61 ( Suppl 1 ): A266 .
5. Kazda, C. M., S. A. Headlee, Y. Ding, R. P. Kelly, P. Garhyan, T. A. Hardy, and A. J. Lewin . 2013 . The glucagon receptor antagonist LY2409021 signifi cantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study. Diabetologia . 56 ( Suppl 1 ): S391.
6. Kelly, R. P., P. Garhyan, E. Raddad, H. Fu, C. N. Lim, M. J. Prince, J. A. Pinaire, M. T. Loh, and M. A. Deeg . 2015 . Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy subjects and patients with type 2 diabetes. Diabetes Obes. Metab. 17 : 414 - 422 .
7. Morgan, E., A. Smith, L. Watts, S. Xia, W. Cheng, R. Geary, and S. Bhanot . 2014 . ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy. Diabetes . 63 ( Suppl 1A ): LB28 .
8. Colhoun, H. M., D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. Neil, S. J. Livingstone, M. J. Thomason, M. I. Mackness, V. Charlton-Menys, and J. H. Fuller . 2004 . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet . 364 : 685 - 696 .
9. Betteridge, J. 2005 . Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am. J. Med. 118 ( Suppl 12A ): 10 - 15 .
10. Howard, B. V., D. C. Robbins, M. L. Sievers, E. T. Lee, D. Rhoades, R. B. Devereux, L. D. Cowan, R. S. Gray, T. K. Welty, O. T. Go, et al . 2000 . LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 20 : 830 - 835 .
11. Shiao, L. L., M. A. Cascieri, M. Trumbauer, H. Chen, and K. A. Sullivan . 1999 . Generation of mice expressing the human glucagon receptor with a direct replacement vector. Transgenic Res. 8 : 295 - 302 .
12. Dallas-Yang, Q., X. Shen, M. Strowski, E. Brady, R. Saperstein, R. E. Gibson, D. Szalkowski, S. A. Qureshi, M. R. Candelore, J. E. Fenyk-Melody, et al . 2004 . Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur. J. Pharmacol. 501 : 225 - 234 .
13. Bosner, M. S., L. G. Lange, W. F. Stenson, and R. E. Ostlund Jr . 1999 . Percent cholesterol absorption in normal women and men quantifi ed with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. 40 : 302 - 308.
14. Ni, Y. G., S. Di Marco, J. H. Condra, L. B. Peterson, W. Wang, F. Wang, S. Pandit, H. A. Hammond, R. Rosa, R. T. Cummings, et al . 2011 . A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52 : 78 - 86 .
15. Castro-Perez, J., F. Briand, K. Gagen, S. P. Wang, Y. Chen, D. G. McLaren, V. Shah, R. J. Vreeken, T. Hankemeier, T. Sulpice, et al . 2011 . Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52 : 1965 - 1973 .
16. Folch, J., M. Lees, and G. H. Sloane Stanley . 1957 . A simple method for the isolation and purifi cation of total lipides from animal tissues. J. Biol. Chem. 226 : 497 - 509 .
17. Shah, V., K. Herath, S. F. Previs, B. K. Hubbard, and T. P. Roddy . 2010 . Headspace analyses of acetone: a rapid method for measuring the 2H-labeling of water. Anal. Biochem. 404 : 235 - 237 .
18. Previs, S. F., A. Mahsut, A. Kulick, K. Dunn, G. Andrews-Kelly, C. Johnson, G. Bhat, K. Herath, P. L. Miller, S. P. Wang, et al . 2011 . Quantifying cholesterol synthesis in vivo using (2)H(2)O: enabling back-to-back studies in the same subject. J. Lipid Res. 52 : 1420 - 1428 .
19. Turley, S. D., M. W. Herndon, and J. M. Dietschy . 1994 . Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J. Lipid Res. 35 : 328 - 339 .
20. Zilversmit, D. B. and L. B. Hughes . 1974 . Validation of a dualisotope plasma ratio method for measurement of cholesterol absorption in rats. J. Lipid Res. 15 : 465 - 473.
21. Zhou, H., W. Li, S. P. Wang, V. Mendoza, R. Rosa, J. Hubert, K. Herath, T. McLaughlin, R. J. Rohm, M. E. Lassman, et al . 2012 . Quantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water. J. Lipid Res. 53 : 1223 - 1231 .
22. Jensen, K. K., S. F. Previs, L. Zhu, K. Herath, S. P. Wang, G. Bhat, G. Hu, P. L. Miller, D. G. McLaren, M. K. Shin, et al . 2012 . Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantifi cation. Am. J. Physiol. Endocrinol. Metab. 302 : E209 - E217 .
23. Xiong, Y., J. Guo, M. R. Candelore, R. Liang, C. Miller, Q. Dallas- Yang, G. Jiang, P. E. McCann, S., A. Qureshi, X. Tong, et al . 2012 . Discovery of a novel glucagon receptor antagonist N-[(4- {(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1Hpyrazol- 1-yl]ethyl}phenyl)carbo nyl]- - -alanine (MK-0893) for the treatment of type II diabetes. J. Med. Chem. 55 : 6137 - 6148 .
24. Mu, J., S. A. Qureshi, E. J. Brady, E. S. Muise, M. R. Candelore, G. Jiang, Z. Li, M. S. Wu, X. Yang, Q. Dallas-Yang, et al . 2012 . Antidiabetic effi cacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One . 7 : e49572 .
25. Conner, S. E., G. Zhu, inventors; Eli Lilly and Company, assignee. Glucagon receptor antagonists, preparation and therapeutic uses. United States patent US7816557. 2010 Oct 19 .
26. Engel, S. S., R. Teng, R. J. Edwards, M. J. Davies, K. Kaufman, and B. J. Goldstein . 2011 . Effi cacy and safety of the glucagon receptor antagonist, MK-0893, in combination with metformin or sitagliptin in patients with type 2 diabetes mellitus. Diabetologia . 54 ( Suppl 1 ): S86 .
27. Edwards, P. A., D. Lemongello, and A. M. Fogelman . 1979 . The effect of glucagon, norepinephrine, and dibutyryl cyclic AMP on cholesterol effl ux and on the activity of 3-hydroxy-3-methylglutaryl CoA reductase in rat hepatocytes. J. Lipid Res. 20 : 2 - 7.
28. Wang, S. P., E. Daniels, Y. Chen, J. Castro-Perez, H. Zhou, K. O. Akinsanya, S. F. Previs, T. P. Roddy, and D. G. Johns . 2013 . In vivo effects of anacetrapib on prebeta HDL: improvement in HDL remodeling without effects on cholesterol absorption. J. Lipid Res. 54 : 2858 - 2865 .
29. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al . 2000 . Role of LXRs in control of lipogenesis. Genes Dev. 14 : 2831 - 2838 .
30. Miettinen, T. A., R. S. Tilvis, and Y. A. Kesaniemi . 1989 . Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism . 38 : 136 - 140 .
31. Lakoski, S. G., F. Xu, G. L. Vega, S. M. Grundy, M. Chandalia, C. Lam, R. S. Lowe, M. E. Stepanavage, T. A. Musliner, J. C. Cohen, et al . 2010 . Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95 : 800 - 809 .
32. Gelling, R. W., X. Q. Du, D. S. Dichmann, J. Romer, H. Huang, L. Cui, S. Obici, B. Tang, J. J. Holst, C. Fledelius, et al . 2003 . Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA . 100 : 1438 - 1443 .
33. Ali, S., B. J. Lamont, M. J. Charron, and D. J. Drucker . 2011 . Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J. Clin. Invest. 121 : 1917 - 1929 .
34. Drucker, D. J. 2001 . Glucagon-like peptide 2. J. Clin. Endocrinol. Metab. 86 : 1759 - 1764.
35. Grigoryan, M., M. H. Kedees, M. J. Charron, Y. Guz, and G. Teitelman . 2012 . Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology . 153 : 3076 - 3088 .
36. Hein, G. J., C. Baker, J. Hsieh, S. Farr, and K. Adeli . 2013 . GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes . 62 : 373 - 381 .
37. Drucker, D. J., P. Erlich, S. L. Asa, and P. L. Brubaker . 1996 . Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA . 93 : 7911 - 7916 .
38. Sudhop, T., M. Reber, D. Tribble, A. Sapre, W. Taggart, P. Gibbons, T. Musliner, K. von Bergmann, and D. Lutjohann . 2009 . Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res. 50 : 2117 - 2123 .
39. Caren, R., and L. Carbo . 1956 . Pancreatic alpha-cell function in relation to cholesterol metabolism. J. Clin. Endocrinol. Metab. 16 : 507 - 516 .
40. Caren, R., and L. Corbo . 1960 . Glucagon and cholesterol metabolism. Metabolism . 9 : 938 - 945 .
41. Eaton, R. P. 1973 . Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res. 14 : 312 - 318 .
42. Bilheimer, D. W., J. L. Goldstein, S. M. Grundy, and M. S. Brown . 1975 . Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J. Clin. Invest. 56 : 1420 - 1430 .
43. Aubry, F., Y. L. Marcel, and J. Davignon . 1974 . Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia. Metabolism . 23 : 225 - 238 .
44. Gu, W., H. Yan, K. A. Winters, R. Komorowski, S. Vonderfecht, L. Atangan, G. Sivits, D. Hill, J. Yang, V. Bi, et al . 2009 . Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Ther. 331 : 871 - 881 .
45. Persson, L., C. Galman, B. Angelin, and M. Rudling . 2009 . Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology . 150 : 1140 - 1146 .
46. Rudling, M., and B. Angelin . 1993 . Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo. J. Clin. Invest. 91 : 2796 - 2805 .
47. Han, S., T. E. Akiyama, S. F. Previs, K. Herath, T. P. Roddy, K. K. Jensen, H. P. Guan, B. A. Murphy, L. A. McNamara, X. Shen, et al . 2013 . Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice. J. Lipid Res. 54 : 2615 - 2622.
48. Vuguin, P. M., and M. J. Charron . 2011 . Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes. Metab. 13 ( Suppl 1 ): 144 - 150 .
49. Hsieh, J., C. Longuet, A. Maida, J. Bahrami, E. Xu, C. L. Baker, P. L. Brubaker, D. J. Drucker, and K. Adeli . 2009 . Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 137: 997-1005.
50. Woollett, L. A., D. D. Buckley, L. Yao, P. J. Jones, N. A. Granholm, E. A. Tolley, P. Tso, and J. E. Heubi . 2004 . Cholic acid supplementation enhances cholesterol absorption in humans. Gastroenterology . 126 : 724 - 731 .
51. Tremblay, A. J., B. Lamarche, V. Lemelin, L. Hoos, S. Benjannet, N. G. Seidah, H. R. Davis Jr ., and P. Couture . 2011 . Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J. Lipid Res. 52 : 558
52. Engelking, L. J., M. R. McFarlane, C. K. Li, and G. Liang . 2012 . Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J. Lipid Res. 53 : 1359 - 1368 .
53. Parker, H. E., K. Wallis, C. W. le Roux, K. Y. Wong, F. Reimann, and F. M. Gribble . 2012 . Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165 : 414 - 423 .
54. Haeusler, R. A., B. Astiarraga, S. Camastra, D. Accili, and E. Ferrannini . 2013 . Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes . 62 : 4184 - 4191 .
55. Bolen, S., L. Feldman, J. Vassy, L. Wilson, H. C. Yeh, S. Marinopoulos, C. Wiley, E. Selvin, R. Wilson, E. B. Bass, et al . 2007 . Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 147 : 386 - 399 .
56. Alrefai, W. A., F. Annaba, Z. Sarwar, A. Dwivedi, S. Saksena, A. Singla, P. K. Dudeja, and R. K. Gill . 2007 . Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: Role of sterol regulatory element binding protein 2. Am. J. Physiol. Gastrointest. Liver Physiol. 292 : G369 - G376.
57. Davis, H. R. Jr ., L. J. Zhu, L. M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S. P. Iyer, M. H. Lam, E. G. Lund, et al . 2004 . Niemann- Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279 : 33586 - 33592 .
58. Pramfalk, C., Z. Y. Jiang, and P. Parini . 2011 . Hepatic Niemann- Pick C1-like 1. Curr. Opin. Lipidol. 22 : 225 - 230.
59. Davis, H. R. Jr ., A. M. Tershakovec, J. E. Tomassini, and T. Musliner . 2011 . Intestinal sterol transporters and cholesterol absorption inhibition. Curr. Opin. Lipidol. 22 : 467 - 478 .